NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study
The purpose of this post approval study is to further characterize the safety profile of the ProGEL™ Pleural Air Leak Sealant in commercial use, with specific reference to long-term safety over 90 days of follow-up.
Lung Cancer|Lung Tumor
OTHER: Control|DEVICE: ProGEL Pleural Air Leak Sealant with standard surgical closure|DEVICE: ProGEL Pleural Air Leak Sealant without standard surgical closure
Safety Endpoints, * Pulmonary adverse events: pneumothorax, persistent air leak, late onset air leak, residual pleural space, and acute respiratory distress syndrome
* Renal adverse events
* Cardiac adverse events
* Death (all causes)
* Hospital readmission, 90 days
Patients having open thoracotomy involving lung resection surgery will be considered for the study. Subjects will be examined for adverse events and complications from either the treatment or the procedure. Follow-up visits are required at 30 days and 90 days after the surgery.